It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) or chronic non-infectious uveitis (CNU) and monitor anti-drug antibodies (ADAbs) formed as part of an immune response to treatment with the fully human monoclonal therapeutic antibody Adalimumab. Adalimumab derived synthetic peptides were optimized for maximum immunogenicity and were tested by SP-ELISA on a development cohort of 18 JIA and CNU treated patients. The two best performing peptides able to differentiate patient groups were selected for evaluation with a larger scale ELISA testing on a total of 29 sera from pediatric patients with JIA or CNU. The results of this peptide-based assay were compared to an in-house developed SPR biosensor ADAbs assay and a commercially available bridging ELISA. The first peptide, termed HC3, was able to positively detect ADAbs in 7 out of the 29 sera, while the second peptide, called LC3, was able to detect ADAbs in 11 out of 29 sera in the evaluation group. Following statistical data evaluation, it has been found that the detection of ADAbs using the peptide-based ELISA assay positively correlates with disease progression and remission. Two synthetic peptides derived from Adalimumab may provide a beneficial tool to clinicians for monitoring patient response to such treatment and taking informed decisions for treatment alternatives.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 CY Cergy Paris Université, Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, Neuville sur Oise, France (GRID:grid.507676.5); Fischer analytics GmbH, Weiler, Germany (GRID:grid.507676.5)
2 AOU Meyer, Pediatric Rheumatology Unit, Florence, Italy (GRID:grid.413181.e) (ISNI:0000 0004 1757 8562)
3 University of Florence, Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, Sesto Fiorentino, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
4 University Hospital of Udine, Department of Medicine, Udine, Italy (GRID:grid.411492.b)
5 CY Cergy Paris Université, Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, Neuville sur Oise, France (GRID:grid.507676.5); University of Florence, Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, Sesto Fiorentino, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
6 CY Cergy Paris Université, Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, Neuville sur Oise, France (GRID:grid.507676.5)
7 University of Milano, Department of Clinical Sciences and Community Health, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
8 CY Cergy Paris Université, Peptlab@UCP Platform of Peptide and Protein Chemistry and Biology and UMR 8076 CNRS-BioCIS, CNRS, Neuville sur Oise, France (GRID:grid.507676.5); University of Florence, Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry “Ugo Schiff”, Sesto Fiorentino, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
9 AOU Meyer, Pediatric Rheumatology Unit, Florence, Italy (GRID:grid.413181.e) (ISNI:0000 0004 1757 8562); University of Florence, Department of NeuroFarBa, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)